- Continued stable growth despite restructuring of commercial organization, and satisfactory start in the US with significant opportunities ahead
- Restructuring program completed with planned cost reduction expected 2024
- 510(k)-process ongoing with
US FDA for big toe implant
"Despite significantly restructuring our sales force, we ended the year with another record quarter. On average, we have grown our gross order intake by more than 50% during the last five quarters. During 2023, the gross order intake reached
Fourth quarter 2023 compared to 2022, Group
» Gross order intake amounted to
» Group net sales amounted to
» Loss for the period amounted to
» Earnings per share amounted to
Twelve months 2023 compared to 2022, Group
» Gross order intake amounted to
» Group net sales amounted to
» Loss for the period amounted to
» Earnings per share amounted to
Significant events during the fourth quarter 2023
» First commercial case in the US was performed
»
Significant events after the quarter
» Results from up to 10 years follow-up of Episealer® patients were accepted for presentation
For more information, please contact:
Pål Ryfors, CEO,
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com
About
The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on
https://news.cision.com/episurf/r/year-end-report-1-january---31-december-2023,c3925457
https://mb.cision.com/Main/14691/3925457/2593288.pdf
(c) 2024 Cision. All rights reserved., source